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Abstract
Background: We previously showed a tumor-suppressive function of S100A14
in oral squamous cell carcinoma (OSCC). This study aimed to examine the
prognostic significance and differentiation-related function of S100A14
in OSCC.
Methods: S100A14 expression was examined in 170 OSCCs from Norwegian
and Nepalese populations using immunohistochemistry. Pro-differentiation
function was investigated by overexpressing and silencing S100A14 expression
in OSCC-derived cells. External transcriptomic datasets were used to validate
association between S100A14 and differentiation markers in OSCC.
Result: Loss of S100A14 expression at the invading tumor fronts significantly
correlated with poor differentiation and reduced 10-years survival of OSCC-
patients. Multivariate Cox analysis identified S100A14 to be an independent
prognostic factor. Modulation of S100A14 expression in OSCC-derived cells
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positively correlated with the expression of differentiation markers. Analysis of
external datasets supported the pro-differentiation function of S100A14.
Conclusion: These results indicate that S100A14 is a pro-differentiation pro-
tein and its expression might be useful as a prognostic marker in OSCC.
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1 | INTRODUCTION
Oral squamous cell carcinoma (OSCC) accounts for more
than 90% of oral cancer (OC) cases. Combined with
lip and pharyngeal cancers, OC is the seventh most com-
mon cancer type in the world.1,2 In spite of the recent
improvements in diagnostic and treatment methods, the
5-year survival (approximately 60%) of OSCC patients has
not improved significantly.3 This emphasizes the need for
better understating of OSCC biology, which might lead
the development of biomarker-based tools for earlier
diagnosis and targeted therapy of OSCC.
S100A14 protein is one of the members of a large
multifunctional group of calcium binding proteins.4
Differential expression of S100A14 seems to be a common
molecular change in human malignancies4-7 and its expres-
sion pattern has been shown to predict disease aggressive-
ness and patient prognosis in breast,6,8 gastric,9 ovarian10,11
and other malignancies.5,12 Functionally, S100A14 has been
implicated to have a key role in molecular pathways related
to cell proliferation, differentiation and apoptosis, as well as
migration and invasion in several cancer types.6,9,13 The
role of S100A14 in cellular differentiation is especially
important as genes encoding several of the S100 protein
members including S100A14 are clustered in the epidermal
differentiation complex on chromosome 1q21,4,14,15 and
many of the S100 members have been shown to have a key
role in cellular differentiation and differentiation-related
pathologies.16,17 Indeed, S100A14 has been shown to pro-
mote differentiation of esophageal squamous cell carci-
noma5 and gastric cancer cells.9
Previously, we reported progressive downregulation of
S100A14 during the progression of OSCC both in vivo and
in vitro.18,19 Further work demonstrated that S100A14
might function as a tumor suppressor protein in OSCC by
inhibiting cell proliferation and invasion, possibly through
the modulation of p53, p21, MMP1, and MMP9 expres-
sion.18,19 S100A14 was further found to interact with and
regulate the expression of S100A16, another member of
S100 protein family found to suppress OSCC progression
by promoting OSCC cell differentiation.20,21 Nevertheless,
the role of S100A14 in OSCC cell differentiation and its
prognostic role in OSCC is currently unknown. In the
current study, using a large cohort of OSCC, we show that
lower expression of S100A14 at the invading fronts/islands
in OSCC specimens is associated with poor tumor differen-
tiation and worse prognosis. Experimentally, retroviral
mediated overexpression and knockdown of S100A14 led
to respective up- and down-regulation of differentiation
markers in OSCC cells.
2 | MATERIALS AND METHODS
2.1 | Formalin-fixed paraffin embedded
(FFPE) human tissue specimens
The tissue samples used in the current work consisted of
FFPE archival OSCC specimens from Norway (Bergen
and Tromsø) and Nepal (Chitwan). Tissue samples from
Bergen, Tromsø, and Chitwan were collected respectively
from Haukeland University Hospital (between 1998 and
2012), University Hospital of North Norway (between
1998 and 2002) and B.P. Koirala Memorial Cancer Hospi-
tal (between 2011 and 2014). Informed consent was
obtained from the participating patients. Collection of
specimens from Bergen was approved by the Committee
for Medical and Health Research Ethics in West Norway
(2010/481 REK vest), from Tromsø by Committee for Med-
ical and Health Research Ethics in North Norway
(2015/1383 REK nord) and from Nepal by the Committee
for Medical and Health Research Ethics in West Norway
(2011/1244 REK vest) and Nepal Health Research Council
(ref 526/2012). A total number of 183 FFPE OSCCs from
Norway (Bergen: 64 and Tromsø: 46) and Nepal (73) were
used for S100A14 immunohistochemistry (IHC). Protocols
used for the tissue collection, processing (formalin fixation
and paraffin embedding) and storage were similar at Ber-
gen and Tromsø. A similar protocol was also established
(by DS) and followed at the B.P. Koirala Memorial Cancer
Hospital. Out of 183 specimens stained, 8 specimens were
excluded from the final analysis because they either con-
sisted of very little tumor tissue or very few invading areas.
Out of the remaining175 specimens (Bergen: 63, Tromsø:
43, and Chitwan: 69), five cases (all from Norway) were
found to be human papilloma virus (HPV) positive and
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were excluded from the final statistical analysis. All
OSCC patients included in the study were newly diag-
nosed cases, and had no history of chemo- or radiother-
apy prior to surgery. Details of the clinicopathological
information of these OSCC cases are reported in Table 1.
REMARK guidelines22 were followed where appropriate.
2.2 | S100A14 IHC
Using rabbit polyclonal anti-human S100A14 primary
antibody (10489-1-AP, Proteintech, Chicago, Illinois,
1:1000 dilutions), IHC was performed on FFPE OSCC
specimens as described previously.18,20 The negative con-
trols consisted of sections incubated with 3% bovine
serum albumin (BSA) instead of the primary antibody.
2.3 | S100A14 IHC evaluation
The stained slides were scanned at ×40 using Nano
Zoomer XR digital scanner, Hamamatsu) and analyzed
manually at ×40 using Aperio ImageScope (version
12.3.2.8013) software, Leica Biosystems. Blinded for the
clinical information and after being calibrated to mini-
mize the interobservation variation, the IHC evaluation
was done by two of the authors (DS and SS). The semi-
quantitative evaluation of S100A14 expression was done
both at the tumor center and at the invading front follow-
ing a composite scoring system as described previously
for S100A16 protein.21 Briefly, three consecutive fields
(>500 cells/field, whenever possible) both at the tumor
center and the invading front (the deepest part of an
invasive tumor, >3 to 4 cell layers thick) were used for
evaluation. In cases where clear invasive fronts were not
possible to identify, deepest invading tumor islands con-
sisting of >50 cells were used for evaluation. A composite
percentage, localization and intensity (PLI) scoring sys-
tem combining the number of S100A14 positive cells
(P score), cellular localization (membranous or cytoplas-
mic or both, L score) and intensity (I score) was used for
S100A14 scoring as described previously.21
2.4 | p16 IHC for HPV
HPV status of OSCCs was investigated by using IHC for
p16 protein in the FFPE tissues. The procedures for anti-
gen retrieval, blocking, and visualization of the antigen
were similar as described for S100A14 IHC. The primary
and the secondary antibodies were mouse monoclonal
anti-human p16 primary antibody (G175-405 clone, BD
Pharminogen, 1:1000 dilutions) and anti-mouse secondary
antibody conjugated with horseradish peroxidase labeled
polymer (K400111-2 EnVision System, DAKO), respec-
tively. Known HPV positive FFPE specimens of oropha-
ryngeal squamous cell carcinoma were used as positive
controls. The negative controls consisted of sections incu-
bated with 3% BSA instead of the primary antibody. OSCC
cases with more than 70% p16 positive cancer cells (both
nuclear and cytoplasmic) were considered HPV positive.
TABLE 1 S100A14 expression (PLI score) and
clinicopathological variables of the OSCC patients from Norway
and Nepal
PLI score at invading fronts/
islandsa




≤60 41 (50.0) 41 (50.0) 1.00
>60 44 (50.0) 44 (50.0)
Gender
Female 27 (47.4) 30 (52.6) .626
Male 58 (51.3) 55 (48.7)
Smoking
No 26 (42.6) 35 (57.4) .036
Yes 49 (50.5) 48 (49.5)
Unknown 10 (83.3) 2 (16.7)
Alcohol
No 19 (30.2) 44 (69.8) .000
Yes 38 (59.4) 26 (40.6)
Unknown 28 (65.1) 15 (34.9)
Location
Tongue 39 (54.9) 32 (45.1) .654
Gingiva and buccal
mucosa
32 (45.1) 39 (54.9)
Floor of the mouth 11 (47.8) 12 (52.2)
Palate, lip and oro-
pharynx
3 (60.0) 2 (40.0)
Differentiation
Poor and moderate 62 (78.5) 17 (21.5) .000
Well 23 (25.3) 68 (74.7)
Lymph node involvementc
Negative (N0) 50 (49.5) 51 (50.1) .950
Positive (N1 and N2) 34 (50.0) 34 (50.0)
Tumor size
T1 and T2 46 (58.2) 33 (41.8) .046
T3 and T4 39 (42.9) 52 (57.1)
Recurrenced
(Continues)
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2.5 | External databases
mRNA expression levels of S100A14 and differentiation
related molecules (IVL, KRT13, KRT4, TGM1, and FLG)
were obtained from TCGA23 and two external microarray
datasets24,25 for OSCC/head and neck squamous cell
carcinoma. These data were used for correlation analyses.
Correlation analysis for TCGA dataset was carried out
using open access cBioPortal for Cancer Genomics tool.26,27
2.6 | Cell culture, construction of
expression, and shRNA vectors and
transfection
The OSCC-derived CaLH328 and VB629 cell-lines were
cultured in humidified environment at 37C with 5% CO2
as described previously.18 S100A14 expression vector
was constructed as described previously.18,20 Briefly,
human cDNA encoding S100A14 was subcloned into the
pRetroX-IRES-ZsGreen1 retroviral expression vector (cat-
no: 632520, Clontech) for the construction of S100A14
expression vector. For shRNA, oligonucleotides targeting
S100A14 mRNA were annealed and inserted in the
RNAi-Ready pSIREN-RetroQ-DsRed-Express expression
vector (cat. no: 632487, Clonetech). For details of the
expression and shRNA vector construction, see Supple-
mentary methods. CaLH3 and VB6 cells infected with
retrovirus with S100A14 insert were referred to as
“S100A14 CaLH3” and “S100A14 VB6”, whereas the cells
infected with and retrovirus without S100A14 insert were
called and “control CaLH3 and control VB6,” respec-
tively. Similarly, CaLH3 cells infected with retrovirus
with shRNA targeting S100A14 and shRNA targeting
LacZ gene were referred to as “S100A14 shRNA CaLH3”
and “LacZ shRNA CaLH3,” respectively.
2.7 | Immunoblotting
Twenty to thirty μg of reduced cell lysates were resolved
in 4% to 20% Criterion TGX Precast Midi Protein Gel (Cat
no: 5671093, Biorad) and immunoblotted with antibodies
as described in Table S1.
2.8 | Statistics
SPSS 25 and/or GraphPad prism version 8.0.1 for Win-
dows (www.graphpad.com) were used for statistical
analysis. Difference between the means of two groups
was analyzed by using paired/unpaired t tests. Pearson
correlation analysis was used to examine correlation
between mRNA levels of S100A14 and keratinocyte dif-
ferentiation markers in external microarray datasets.
OSCC cases were categorized into high- and low-
S100A14 expression groups using the median PLI
scores both at the tumor center and at the invading
front/island as cut-off values. Because of the fewer
number of OSCC cases (5.9%) with poor differentiation,
these cases were merged together with OSCCs with
moderate differentiation. Hence, only two groups (well
vs moderately-poorly differentiated OSCCs) were con-
sidered for statistical analysis. Association between the
S100A14 expression and other binary variables was
examined using chi-square test. Survival analysis was
performed using the Kaplan-Meier analysis (log-rank
test). Clinicopathological variables with significant associa-
tion with 10-year overall survival in univariate Cox analy-
sis were used to create a model for multivariate Cox
proportional hazard analysis. Specimens from Nepal were
excluded from the survival analysis, as the survival data
were not available for them. Level of significance was set
at 5%.
3 | RESULTS
3.1 | HPV status
Five OSCC cases (four from tongue and one from lip)
from Norwegian cohort were positive for p16 (more than
70% p16 positive cancer cells, both nuclear and cytoplas-
mic) suggesting positivity for HPV infection. None of the
samples from Nepal tested positive for HPV. Only the
HPV negative cases were used for statistical analysis.
TABLE 1 (Continued)
PLI score at invading fronts/
islandsa
Variables Low, n (%) High, n (%)
P-
value
No 26 (60.5) 17 (39.5) .761
Yes 11 (64.7) 6 (35.3)
Tumor stagec
Early (I and II) 32 (56.1) 25 (43.9) .233
Late (III and IV) 52 (46.4) 60 (53.6)
Note: The bold italic values were used to indicate significant p < .05.
Abbreviation: OSCC, oral squamous cell carcinoma, PLI, percentage,
localization and intensity.
aOSCCs were stratified into high and low S100A14 expression groups by
using median S100A14 PLI score as a cut-off.
bPatients were categorized into low- and high-age groups based on the median age.
cData on node status and stage were missing for one OSCC case from Tromsø.
dData on recurrence were not available for all OSCC cases from Tromsø and Nepal.
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FIGURE 1 S100A14 protein was downregulated at the invading front/island of majority of moderately-poorly differentiated OSCC and low
S100A14 protein expression correlated with poor OSCC prognosis. A, Graphic illustration of S100A14 PLI score demonstrated downregulation of
S100A14 at the invading front/island of OSCC as compared to the corresponding tumor center of OSCC lesions. Paired t tests test was used for the
statistical analysis. The horizontal bars indicate mean PLI scores. B, Representative well-differentiated OSCC lesion demonstrating strong, mostly
membranous S100A14 staining at both the tumor center (b1) and the invading front area (b2). C, Representative images of poorly differentiated
OSCC lesion showing a gradient of S100A14 expression: central area (c1) showed a relatively strong, membranous staining in contrast to almost
undetectable staining in the invading front area (c2, arrowheads indicated tumor cells). S100A14 PLI score was found to be significantly higher
both at the tumor center, D, and at the invading fronts/islands, E, in well-differentiated OSCCs as compared to that of moderately-poorly
differentiated lesions. Unpaired t tests test was used for the statistical analysis in D and E. The error bars represent SEM. F, Kaplan-Meier curves
showing reduced 10-year survival probabilities for patients with low S100A14 PLI score at the invading front/island. Log-Rank test was used for
statistical analysis. OSCC, oral squamous cell carcinoma [Color figure can be viewed at wileyonlinelibrary.com]
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3.2 | S100A14 expression was
downregulated at the invading fronts/
islands of OSCC
Almost all of the OSCC specimens expressed S100A14 in
cancer cells and/or the adjacent normal/dysplastic epithe-
lium (if present). However, S100A14 expression pattern
was highly variable across the different locations of the
same OSCC lesion. Overall, the expression was weaker at
the invading fronts/islands (poorly differentiated regions)
as compared to central/superficial areas (more differenti-
ated regions). Indeed, semiquantitative evaluation showed
that S100A14 PLI score was significantly lower (P < .0001)
at the invading front/island as compared to the central
location of corresponding OSCCs (Figure 1A). Majority of
the well differentiated OSCC specimens demonstrated a
moderate to strong membranous S100A14 expression both
at the superficial/central areas as well as at the invading
front/islands (Figure 1B). Most of the moderately-poorly
differentiated OSCCs, however, expressed moderately
strong, membranous S100A14 staining at the tumor cen-
ter, whereas the staining was very weak or negative at the
invading front/island of tumor cells (Figure 1C). Addition-
ally, although weak, the S100A14 expression appeared
more cytoplasmic in the invading front/islands in the
moderately-poorly differentiated OSCCs (Figure 1C and
c2). Indeed, when stratified with respect to the differentia-
tion status, S100A14 PLI score for well differentiated
OSCC lesions was significantly higher both at the tumor
center (Figure 1D) as well as at the invading front/island
(Figure 1E) as compared to the corresponding areas of
moderately and poorly differentiated lesions. Except occa-
sional inflammatory cells, none of the structures in the
stroma expressed S100A14.
3.3 | Loss of S100A14 expression at the
invading front/islands of OSCC correlated
negatively with tumor differentiation and
10-years overall survival
Examination of possible correlation between S100A14
expression and clinicopathological variables showed that
low S100A14 PLI score at the invading front/island
was significantly associated with moderate-poorly differenti-
ated OSCCs (P < .0001), alcohol drinking habit (P < .0001),
smoking (P = .036) and tumor size (P = .046) (Table 1).
Norwegian and Nepalese specimens when analyzed
separately, no significant correlation was observed between
the S100A14 PLI score at the invading front/island and
clinical parameters, except for the tumor differentiation
(Norwegian cases, P < .0001); Nepalese cases, P = .002)
(Tables S2 and S3).
Survival analysis showed a significant correlation
between the reduced expression of S100A14 at the invad-
ing front/island (Log-Rank test, P = .003), higher age
(Log-Rank test, P = .027), poorer tumor differentiation
(Log-Rank test, P = .01), node positive status (Log-Rank
test, P = .009) or higher pathological stage (Log-Rank test,
P = .001) with reduced 10-years overall survival of OSCC
TABLE 2 Results of a multivariate
Cox regression analysis for predicting
the overall survival of OSCC cases
Univariate Cox Multivariate Cox
Variables HR 95% CI P-value HR 95% CI P-value
S100A14
Low 0.49 0.30-0.79 .004 0.55 0.32-0.96 .035
High
Age
≤63 1.70 1.05-2.73 .029 1.77 1.07-2.94 .025
>63
Differentiation
Well 1.86 1.14-3.03 .012 1.51 0.86-2.66 .148
Mod. and poor
Node status
N0 1.89 1.16-2.07 .01 1.29 0.72-2.30 .385
N1 and N2
Clinical stage
Early (I and II) 2.28 1.38-3.76 .001 1.88 1.02-3.47 .043
Late (III and IV)
Abbreviations: CI, confidence interval; HR, hazard ratio; Mod., moderate; OSCC, oral squamous cell
carcinoma.
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patients. Univariate Cox analysis showed S100A14 expres-
sion, age, differentiation, node status and clinical stage to
be significantly associated with 10-year overall survival.
Multivariate Cox regression analysis demonstrated that
FIGURE 2 S100A14 mRNA expression was positively correlated with differentiation markers in OSCC specimens from external
microarray datasets. mRNA expression levels of S100A14, IVL, KRT13, KRT4, TGM1, and FLG were obtained from external
microarray dataset (A-E, Chen et al, 2008; F-J, Thurlow et al, 2010) and their correlation was examined using Pearson analysis.
mRNA expression levels of S100A14 and the selected keratinocyte differentiation-related makers were found to be significantly
correlated. The x-axis represented the relative mRNA level (arbitrary value) of S100A14, whereas the y-axis represented mRNA levels
for differentiation markers. OSCC, oral squamous cell carcinoma [Color figure can be viewed at wileyonlinelibrary.com]
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S100A14 expression at the invading front/island was an
independent prognostic factor for the survival of OSCC
patients (HR = 0.55, CI = 0.32-0.96, P = .035) (Table 2).
Low PLI score at the tumor center correlated
with moderate-poorly differentiated OSCCs (P < .0001).
Nevertheless, despite a trend for a positive correlation,
the PLI score at the tumor center was not significantly
correlated with 10-year overall survival (Log-Rank test,
P = .056) (data not shown).
3.4 | mRNA expression levels of S100A14
and keratinocyte differentiation markers
correlated significantly in external datasets
of OSCC
A significant positive correlation between the S100A14
PLI score and OSCC differentiation status prompted us
to test this at the molecular level in other cohorts of
OSCCs. Indeed, S100A14 mRNA levels were positively
correlated with mRNA levels of keratinocyte differentia-
tion markers (IVL, KRT13, KRT4, TGM1, and FLG) in
two OSCC microarray24,25 (Figure 2) and TCGA23
datasets (Figure S2).
3.5 | S100A14 overexpression led to
induced expression of differentiation-
related markers in OSCC-derived cells
Having observed a significant positive association between
the expression status of S100A14 and more differentiated
phenotype in OSCC specimens, we next investigated
whether S100A14 could modulate the expression of
differentiation-related markers in OSCC-derived cell-lines.
Retroviral mediated overexpression and knockdown of
S100A14 respectively led to up- and down-regulation of
involucrin, cytokeratin 13 and cytokeratin 4 in CaLH3
cells (Figure 3A,B). Similarly, overexpression of S100A14
was associated with upregulation of involucrin and
cytokeratin 4 in VB6 cells (Figure 3C).
4 | DISCUSSION
We previously reported a loss of S100A14 expression at
the invading front/island (poorly differentiated areas) of
OSCC as compared to the tumor surface/tumor center
(more differentiated areas), suggesting a possible func-
tional link between S100A14 and cellular differentia-
tion.18 In the current study, using S100A14 IHC in a
large cohort of OSCCs, we demonstrated that S100A14
expression positively correlated with tumor differentia-
tion and better patient survival. Further, the use of exter-
nal OSCC datasets and in vitro experiments provided
evidence for pro-differentiation function of S100A14 in
OSCC cells.
Malignancies with more differentiated phenotype often
behave less aggressively and are associated with better clini-
cal outcomes.30,31 Accordingly, molecular regulators with
pro-differentiation function are suggested to have tumor
suppressive functions and they might serve as potential bio-
markers in OSCC management.32,33 Several observations in
the current study provide evidence for a pro-differentiation
function for S100A14 in OSCC. First, the expression of
S100A14 was significantly downregulated at the invading
front/island (poorly differentiated area of a tumor) as com-
pared to the corresponding central area (better differenti-
ated area) of OSCC (Figure 1A). Second, when stratified
with respect to the differentiation status, the well differenti-
ated OSCC lesions expressed significantly higher S100A14
both at the invading front/island and tumor center as com-
pared to the moderately and poorly differentiated lesions
(Figure 1B-E). Similar observations have been reported in
esophageal squamous cell carcinoma5 and gastric cancer.9
Importantly, clinicopathological analysis showed a signifi-
cant correlation between low S100A14 protein (at the
invading front/island) levels and reduced 10-year overall
survival probabilities for OSCC patients (Figure 1F). These
FIGURE 3 Retroviral mediated modulation of S100A14
positively regulated the expression of differentiation-related
markers in OSCC cell-lines. S100A14 was overexpressed and
knocked-down in CaLH3 cells and concomitant modulation of
differentiation markers was examined. Western blot analysis
showed upregulation of differentiation markers (cytokeratin
13, cytokeratin 4 and involucrin) in CaLH3, A, and of cytokeratin
4 and involucrin in VB6 cells, C, with S100A14 overexpression.
Supporting these results, S100A14 knockdown resulted in
downregulation of the corresponding differentiation related
proteins in CaLH3, B. OSCC, oral squamous cell carcinoma
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data suggest that S100A14 expression at the invading front/
island can serve as an independent prognostic factor for
OSCC. Third, S100A14 overexpression or knockdown medi-
ated concomitant modulation of expression of differentia-
tion markers provided direct evidence for a differentiation
promoting function for S100A14 in OSCC cells (Figure 3).
Corroborating these findings, mRNA expression levels of
S100A14 was significantly correlated with mRNA levels
of a number of differentiation markers such as INV,
KRT13, KRT4, TGM1, and FLG in OSCC lesions in three
independent OSCC datasets (Figure 2 and Figure S2). Dif-
ferentiation promoting function of S100A14 in OSCC is in
line with previous studies in esophageal squamous cell car-
cinoma5 and gastric cancer cells.9
Keratinocyte differentiation is a multistep process
involving a complex-interplay between extracellular and
intracellular signals, transcription factors, structural pro-
teins, enzymes and metallic ions such as calcium.34,35 A
previous study suggested involvement of JunB
(a component of AP-1 transcription factor) in S100A14
mediated differentiation of esophageal squamous cell
carcinoma cells.5 However, the signaling molecules
and pathways for prodifferentiation function of S100A14
are not fully understood. We previously showed that
S100A14 positively regulated the expression and function
of tumor suppressor protein p53 and its downstream sig-
naling molecule, the p21, leading to a G1-cell cycle arrest
and reduced OSCC cell proliferation.19 Given the key role
of p5336,37 and p2138 in cell-cycle arrest and keratinocyte
differentiation, a possible involvement of these proteins
in S100A14 mediated prodifferentiation function cannot
be excluded in OSCC. Additionally, cooperation between
S100A14 and S100A16 represents a likely mechanism in
keratinocyte differentiation as S100A14 has been found
to interact with and regulate the expression of S100A16,
which in turn promotes keratinocyte differentiation.21
Nevertheless, these suggestions warrant further in-depth
investigation.
The current project benefited from the inclusion of
OSCC specimens from two different countries (Norway
and Nepal) with differing race, lifestyle, ethnicity and eti-
ological factors. Despite these differences, previous stud-
ies have suggested involvement of common biological
pathways during OSCC development in western and
developing countries.39,40 In parallel, S100A14 was found
to be significantly downregulated at the invading fronts/
islands in poorly differentiated OSCC as compared to the
well differentiated ones in both countries (Figure S1),
indicating that deregulation of S100A14 might be a com-
mon molecular alteration in OSCC irrespective of the
associated risk factors and genetic background of the
individuals.
In conclusion, our results suggest that S100A14 is a
differentiation promoting protein in OSCC. Together
with our previous findings indicating a tumor suppressive
function (inhibition of OSCC cell proliferation and inva-
sion) for S100A14,18,19 it can be suggested that S100A14
is involved in multiple biological processes relevant for
tumor suppression in OSCC. Further studies are neces-
sary to understand S100A14-mediated signaling pathways
and to establish potential use of S100A14 as a prognostic
marker in OSCC.
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